As of June, 8 The EPS for Intec Pharma Ltd. (NTEC) Expected At $-0.28

May 17, 2018 - By Carolyn Hewitt

Intec Pharma Ltd. (NASDAQ:NTEC) Corporate Logo

Investors wait Intec Pharma Ltd. (NASDAQ:NTEC)’s quarterly earnings on June, 8., Zacks reports. Wall Street now sees -28.21 % EPS growth despite Intec Pharma Ltd. last quarter’s EPS of $-0.39. At traded at $4.85 lastly.It’s uptrending since May 17, 2017 and is 25.00% up. The stock outperformed the S&P 500 by 13.45%.

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel.The firm is worth $164.22 million. The Company’s Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.Currently it has negative earnings. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa , which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients.

Intec Pharma Ltd. (NASDAQ:NTEC) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.